Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Buttar

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinasesMatt Addie, Peter Ballard, David Buttar, et al.
Journal of Medicinal Chemistry|January 15, 2019
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader AntagonistsJames S Scott, Andrew Bailey, David Buttar, et al.
Journal of Pharmaceutical Sciences|November 13, 2022
The Global Characterisation of a Drug-Dendrimer Conjugate - PEGylated poly-lysine DendrimerNadim Akhtar, Marianne B Ashford, Louisa Beer, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinasesMatt Addie, Peter Ballard, David Buttar, et al.
Journal of Medicinal Chemistry|January 15, 2019
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader AntagonistsJames S Scott, Andrew Bailey, David Buttar, et al.
Journal of Pharmaceutical Sciences|November 13, 2022
The Global Characterisation of a Drug-Dendrimer Conjugate - PEGylated poly-lysine DendrimerNadim Akhtar, Marianne B Ashford, Louisa Beer, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Pageof 2